| Literature DB >> 27245877 |
Meng Shi1,2, Jianhong Xia3, Huaixin Xing4, Wenjun Yang5, Xiangyu Xiong2, Wenting Pan2, Sichong Han2, Jinhua Shang2, Changchun Zhou6, Liqing Zhou3, Ming Yang1.
Abstract
Metallopeptidase 13 (MMP13), a well-known and highly regulated zinc-dependent MMP collagenase, plays a crucial part in development and progression of esophageal squamous cell carcinoma (ESCC). Therefore, we examined associations between ESCC susceptibility and four haplotype-tagging single nucleotide polymorphisms (htSNPs) using a two stage case-control strategy. Odds ratios (OR) and 95% confidence intervals (95% CI) were computed by logistic regression model. After analyzing 1588 ESCC patients and frequency-matched 1600 unaffected controls, we found that MMP13 rs2252070 G > A genetic polymorphism is significantly associated with ESCC risk in Chinese Han populations (GA: OR = 0.63, 95% CI = 0.54-0.74, P = 1.7 × 10(-6), AA: OR = 0.73, 95% CI = 0.66-0.81, P = 1.8 × 10(-6)). Interestingly, the rs2252070 G-to-A change was shown to diminish a Sp1-binding site in ESCC cells. Reporter gene assays indicated that the rs2252070 A allele locating in a potential MMP13 promoter has low promoter activities. After measuring MMP13 gene expression in sixty-six pairs of esophageal cancer and normal tissues, we observed that the rs2252070 A protective allele carriers showed decreased oncogene MMP13 expression. Results of these analyses underline the support of the notion that MMP13 might function as a key oncogene in esophageal carcinogenesis.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27245877 PMCID: PMC4887914 DOI: 10.1038/srep27013
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Associations between candidate SNPs in the MMP13 and ESCC risk in Jiangsu case-control set (Discovery set).
| No | Identity | Case | Common genotype | Heterozygous genotype | Rare genotype | Allelic OR2 (95% CI) | |
|---|---|---|---|---|---|---|---|
| 1 | rs11225490 T > C | ESCC | 0.580 | 0.359 | 0.061 | 0.89 (0.74–1.08) | 0.251 |
| Control | 0.608 | 0.342 | 0.050 | ||||
| 2 | rs2252070 G > A | ESCC | 0.369 | 0.454 | 0.177 | 0.70 (0.60–0.83) | 2.1 × 10−5 |
| Control | 0.266 | 0.513 | 0.225 | ||||
| 3 | rs17099788 A > G | ESCC | 0.760 | 0.235 | 0.005 | 1.11 (0.87–1.41) | 0.393 |
| Control | 0.750 | 0.232 | 0.018 | ||||
| 4 | rs3758854 G > A | ESCC | 0.835 | 0.160 | 0.005 | 1.09 (0.82–1.44) | 0.569 |
| Control | 0.827 | 0.163 | 0.010 |
Note: SNP, single nucleotide polymorphism; MMP13, matrix metallopeptidase 13; ESCC, esophageal squamous cell carcinoma; OR, odds ratio; CI, confidence interval.
1Data were calculated by logistic regression.
Genotype frequencies of MMP13 rs2252070 genetic variant among patients and controls and their association with ESCC risk.
| Studies | |||||
|---|---|---|---|---|---|
| Genotypes | Cases No. (%) | Controls No. (%) | OR | ||
| Jiangsu set | GG | 217 (36.9) | 157 (26.6) | 1.00 | |
| GA | 267 (45.4) | 308 (51.3) | 0.65 (0.49–0.88) | 0.004 | |
| AA | 104 (17.7) | 135 (22.5) | 0.79 (0.65–0.95) | 0.011 | |
| Shandong set | GG | 382 (38.2) | 274 (27.4) | 1.00 | |
| GA | 463 (46.3) | 513 (51.3) | 0.65 (0.53–0.81) | 8.8 × 10−5 | |
| AA | 155 (15.5) | 213 (21.3) | 0.75 (0.65–0.86) | 4.9 × 10−5 | |
| Pooled | GG | 599 (37.7) | 431 (26.9) | 1.00 | |
| GA | 730 (46.0) | 821 (51.3) | 0.63 (0.54–0.74) | 1.7 × 10−6 | |
| AA | 259 (16.3) | 348 (21.8) | 0.73 (0.66–0.81) | 1.8 × 10−6 | |
Note: ESCC, esophageal squamous cell carcinoma; MMP13, matrix metallopeptidase 13; OR, odds ratio; CI, confidence interval.
1Data were calculated by logistic regression with adjustment for age, sex, smoking and drinking status.
Risk of ESCC associated with MMP13 rs2252070 G > A genotypes by age, sex, smoking status and drinking status.
| Variable | ||||||||
|---|---|---|---|---|---|---|---|---|
| GG | GA | OR | GG | AA | OR | |||
| Sex | ||||||||
| Male | 436/337 | 546/601 | 0.71 (0.59–0.86) | 3.1 × 10−4 | 436/337 | 192/266 | 0.76 (0.67–0.85) | 4.3 × 10−5 |
| Female | 163/94 | 184/220 | 0.47 (0.33–0.67) | 3.2 × 10−5 | 163/94 | 67/82 | 0.69 (0.56–0.87) | 0.001 |
| Age (years) | ||||||||
| ≤57 | 321/226 | 331/429 | 0.56 (0.44–0.70) | 3.8 × 10−5 | 321/226 | 135/161 | 0.78 (0.67–0.90) | 0.001 |
| >57 | 278/205 | 399/392 | 0.77 (0.61–0.97) | 0.026 | 278/205 | 124/187 | 0.71 (0.61–0.82) | 6.7 × 10−5 |
| Smoking status | ||||||||
| No | 265/182 | 359/320 | 0.76 (0.59–0.96) | 0.024 | 265/182 | 131/143 | 0.81 (0.69–0.94) | 0.007 |
| Yes | 334/249 | 371/501 | 0.55 (0.45–0.69) | 5.9 × 10−6 | 334/249 | 128/205 | 0.69 (0.60–0.79) | 7.8 × 10−6 |
| Drinking status | ||||||||
| No | 309/206 | 413/420 | 0.65 (0.52–0.81) | 1.8 × 10−4 | 309/206 | 131/179 | 0.70 (0.60–0.81) | 9.0 × 10−6 |
| Yes | 290/225 | 317/401 | 0.62 (0.49–0.77) | 3.2 × 10−5 | 290/225 | 128/169 | 0.77 (0.67–0.89) | 3.7 × 10−4 |
Abbreviations: ESCC, esophageal squamous cell carcinoma; MMP13, matrix metallopeptidase 13; OR, odds ratio; CI, confidence interval.
1Number of case patients with genotype/number of control subjects with genotype.
2Data were calculated by logistic regression, adjusted for sex, age, smoking, and drinking status, where it was appropriate.
Figure 1Abolishment of a Sp1 binding site in the MMP13 promoter by the rs2252070 G > A genetic variant.
(A) Alibaba 2.1 prediction. (B) Electrophoretic mobility-shift assay (EMSA) with biotin-labeled rs2252070G or rs2252070A probes and KYSE30 nuclear extracts. Lanes 1 and 6, probe only; lanes 3 and 8, probe and nuclear extracts; lanes 2 and 7, probe and nuclear extracts plus 100× unlabeled rs2252070G; lanes 4 and 9, probe and nuclear extracts plus 100× unlabeled rs2252070A; lanes 5 and 10, probe and nuclear extracts plus 100× unlabeled Sp1 consensus probes. (C) Super-EMSA with biotin-labeled rs2252070G or rs2252070A probes, pure recombinant Sp1 protein or Sp1 antibody. Lanes 1, probe only; lanes 2, probe and recombinant Sp1 protein; lanes 3, probe, recombinant Sp1 protein and Sp1 antibody.
Figure 2Transient luciferase reporter gene expression assays with constructs containing different rs2252070 alleles of MMP13 5′-region (A) in KYSE30 cells (B) or KYSE150 cells (C). To standardize transfection efficiency, we cotransfected pRL-SV40 with these reporter gene constructs. Fold-changes were calculated by defining the luciferase activity of cells co-transfected with pGL3-basic as 1. All experiments were performed in triplicates in three independent transfection experiments and each value represents mean ± SD. Compared with pGL3-Basic transfected cells, *P < 0.05; **P < 0.01.
Figure 3MMP13 mRNA expression (mean ± SD) in normal and cancerous esophageal tissues grouped by MMP13 rs2252070 genotypes.
The expression of individual MMP13 mRNA was calculated relative to expression of β-actin using the 2−dCt method. *P < 0.05; **P < 0.01.
Figure 4Silencing Sp1 expression repressed MMP13 expression in KYSE30 and KYSE150 cells.
The expression of individual MMP13 mRNA was calculated relative to expression of β-actin. *P < 0.05. Protein expression of MMP13, Sp1 and GAPDH was detected using Western Blotting.